Quick summary: Emerging research shows that perimenopause triggers a genomic reprogramming process that can age a woman’s biology by six to nine years, silencing the hormone-sensitive genes that protect against cardiovascular disease, osteoporosis, type 2 diabetes, and cognitive decline. Women spend an average of 10.7 years in the gap between lifespan and healthspan, compared to 8.1 years for men, a disparity that is now understood to have measurable molecular causes rather than being an unavoidable feature of female ageing. Genetic testing tools such as Willbe’s FemGene are beginning to make personalised, preventive care a clinical reality, offering women and their clinicians the means to identify individual risk and tailor treatment before the damage accumulates.
Women are living longer than ever. In the UK, the US, Australia, and Spain, a woman born today can expect to outlive her male counterpart by several years. But living longer is not the same as living well. For millions of women, the extra years come at a cost: old age spent managing chronic illness, cognitive decline, bone fractures, and cardiovascular disease. Scientists call the gap between lifespan and healthspan the frailty gap. Women spend an average of 10.7 years in it, compared to 8.1 years for men.
New research is beginning to explain why.
Perimenopause as a reprogramming event
For decades, menopause has been framed as a story of loss. The decline of reproductive hormones marking the end of a biological chapter. But molecular biology is revealing something more complex, and in some ways more consequential, than simply the loss of reproductive function.
Perimenopause, which can begin in a woman’s early forties, is being reconsidered by emerging research as a genomic reprogramming event. A period where shifting hormone levels directly reshape how genes are expressed, influencing how cells age and how the body responds to disease.
The mechanisms are precise and measurable. During perimenopause, key hormone-sensing genes such as ESR1 (the oestrogen receptor) and CYP19A1 (aromatase) undergo progressive hypermethylation, a chemical change that silences them and reduces the body’s capacity to respond to circulating hormones. Chromatin structures in the brain, bones, and cardiovascular tissue shift toward a repressed state. Telomeres, the protective caps on chromosomes, accelerate their shortening. Epigenetic clocks, the molecular tools scientists use to measure biological age, register what the data makes hard to ignore: menopause can age a woman’s biology by six to nine years, independent of her chronological age.
The consequences are not abstract. They correlate directly with the rise in cardiovascular disease, osteoporosis, type 2 diabetes, and cognitive decline that occurs in the decade following menopause. These are not coincidences of timing. They are the downstream effects of hormonal signals silencing the genes that once offered protection.
Where longevity is won or lost
Research from Willbe identifies five domains of female health and longevity that are disproportionately reshaped by the hormonal and genomic changes of perimenopause.
In metabolic health, women entering menopause early carry a 50% higher risk of developing type 2 diabetes, and late perimenopausal women show roughly 30% lower insulin sensitivity compared to their premenopausal selves. Perimenopausal weight gain, long blamed on lifestyle, is in fact the result of oestrogen-sensitive genes like GLUT4, AMPK, and PPARG being progressively silenced. When these metabolic regulators go quiet, the body’s ability to burn fat, maintain insulin sensitivity, and power its mitochondria is fundamentally altered.
Bone health follows a similar pattern. Approximately half of postmenopausal women will receive an osteoporosis diagnosis, and fracture risk carries an estimated 50% genetic component. As oestrogen declines, genes including RANKL, SOST, and RUNX2 shift the balance between bone-building and bone-resorbing cells, accelerating loss at precisely the moment a woman’s genetic predispositions are least buffered by protective hormonal signals.
Cardiovascular disease remains the leading cause of death in women globally, accounting for 30% of female deaths according to the World Heart Federation, yet women are broadly perceived as protected until menopause. That protection evaporates quickly. Early menopause, before the age of 50, increases cardiovascular and stroke risk by roughly 25%, as oestrogen’s regulation of vascular tone and lipid metabolism is withdrawn. After menopause, women’s cardiovascular risk rapidly overtakes that of men.
Brain health is also deeply affected. Up to 62% of women report cognitive difficulties during perimenopause, and 59% of UK women say menopause has had a negative impact on their careers. Oestrogen regulates genes essential for neurotransmitter synthesis and synaptic plasticity. As these pathways are suppressed, APOE e4 carriers, who are disproportionately female, face amplified Alzheimer’s risk, with postmenopausal women showing a steeper rise in dementia incidence than men of the same age.
Biological ageing ties it all together. The longevity genes SIRT1, FOXO3, TERT, and TP53 are hormone-sensitive. With declining oestrogen and testosterone, these protective programmes are progressively switched off, accelerating cellular ageing, reducing DNA repair efficiency, and shortening telomeres. The six-to-nine year acceleration of biological ageing measured by epigenetic clocks is not inevitable. But preventing it requires knowing which genetic pathways are most vulnerable before the damage compounds.
From insight to action
Willbe’s FemGene is the first diagnostic tool designed to assess both sides of the gene-hormone relationship simultaneously. Rather than measuring hormone levels alone, it analyses the genetic architecture that determines how a woman produces, metabolises, detoxifies, and responds to hormones, alongside how her hormone trajectory could reshape her gene expression.
The clinical implications are significant. Two women presenting with identical oestrogen levels and identical symptoms may require entirely different interventions. A woman with reduced ESR1 receptor sensitivity and fast CYP1A1 metabolism will clear oestrogen quickly, leaving her undertreated on a standard HRT dose: her hot flushes unresolved, her bone density declining, her cognitive complaints dismissed. A woman with heightened receptor sensitivity and slow COMT clearance on the same prescription may experience worsening breast tenderness, anxiety, and fluid retention, driving her to discontinue a therapy that, properly calibrated, could have helped protect her brain and heart for decades.
With proper testing, these invisible connections become visible, allowing clinicians to move from trial-and-error prescribing to genuinely personalised, longevity-focused care. It also enables the mapping of genetic predispositions across the five longevity domains, identifying which women are most at risk of accelerated bone loss, metabolic dysfunction, cardiovascular disease, or cognitive decline, so that preventive strategies can be put in place before the damage accumulates.
A new era of women’s longevity medicine
The future of women’s longevity medicine calls for polygenic stratification that can identify risk before symptoms emerge, HRT calibrated not to population averages but to individual genetic architecture, nutritional and lifestyle interventions with epigenetic effects tailored to specific gene variants, and a fundamental reframing of female ageing as something that can be actively shaped rather than passively endured. For women navigating perimenopause today, understanding their genetic blueprint through a female-hormonal lens offers something genuinely new: not just a clearer picture of what is happening in their bodies, but a real chance to influence what happens next.
Vanessa Emslie, PhD is chief medical officer at Willbe, a UK-based company combining genetics, hormone testing, and bioidentical HRT. Willbe’s FemGene platform delivers personalised clinical insights to support hormone therapy and longevity planning.
